The tumor-targeting domains of the bispecific antibodies were also functional, indicated by a strong binding of NKAB-EGFR and less pronounced binding of NKAB-ErbB2 to T98G glioblastoma cells, which express high levels of EGFR and more moderate levels of ErbB2. The gene discussed is EGFR; the disease is glioblastoma.